Sequestration of Plasmodium falciparum-infected erythrocytes in host blood vessels is a key triggering event in the pathogenesis of severe childhood malaria, which is responsible for about one million deaths every year 1 . Sequestration is mediated by specific interactions between members of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family and receptors on the endothelial lining 2 . Severe childhood malaria is associated with expression of specific PfEMP1 subtypes containing domain cassettes (DCs) 8 and 13 (ref. 3 ), but the endothelial receptor for parasites expressing these proteins was unknown 4, 5 . Here we identify endothelial protein C receptor (EPCR), which mediates the cytoprotective effects of activated protein C 6 , as the endothelial receptor for DC8 and DC13 PfEMP1. We show that EPCR binding is mediated through the amino-terminal cysteine-rich interdomain region (CIDRa1) of DC8 and group A PfEMP1 subfamilies, and that CIDRa1 interferes with protein C binding to EPCR. This PfEMP1 adhesive property links P. falciparum cytoadhesion to a host receptor involved in anticoagulation and endothelial cytoprotective pathways, and has implications for understanding malaria pathology and the development of new malaria interventions.
Each P. falciparum parasite genome harbours about 60 var genes encoding different PfEMP1 types, enabling the parasite to attach infected erythrocytes to different receptors on the vascular lining 2 . This attachment drives malaria pathologies, but also prevents the passage of mature-stage infected erythrocytes through the spleen, where they are destroyed. On the basis of the var 59 upstream regions (UPS), PfEMP1 can be divided into groups A-E. In addition, the Duffybinding-like (DBL) and CIDR adhesion domains are subdivided into 147 subclasses (for example, CIDRa1.1) 7 . Despite a high rate of var gene recombination, many tandem domain arrangements-DCshave been maintained through evolution, and are therefore thought to be of functional importance. The best example is DC2, also known as VAR2CSA, which mediates binding in the placenta 8 and is of key importance to the pathogenesis of malaria in pregnancy. Severe malaria in children is associated with expression of a subset of PfEMP1 molecules characterized by DC8 (a unique group B/A chimaeric gene) and DC13 (group A) 3 , but the endothelial receptor(s) for these proteins have remained undefined 4, 5 .
To identify the DC8-PfEMP1 receptor, we produced a full-length DC8-containing PfEMP1 protein encoded by var gene IT4var20 from the FCR3/IT4 parasite. This 288 kilodalton (kDa) His-tagged recombinant protein (rIT4VAR20) was screened against an array of 2,505 full-length human plasma membrane proteins expressed on HEK293 cells ( Supplementary Table 1 ) using the Retrogenix Cell Microarray. One specific hit for rIT4VAR20 identified EPCR as a potential binding partner 9 . EPCR is encoded by the PROCR gene, and is expressed on endothelial cells in most tissues 10 . Protein C binds EPCR, promoting its conversion to activated protein C (APC) 11 . On endothelial cells, APC cleaves protease activated receptor 1 (PAR1) resulting in broad endothelial cytoprotective 12 and anti-inflammatory effects 13 . In the absence of APC-EPCR engagement, PAR1 activation can result in barrierdisruptive effects and activation of pro-inflammatory pathways 13 . In plasma, soluble APC exerts anticoagulative effects by the proteolytic inactivation of blood coagulation factors Va and VIIIa 13 .
To identify the EPCR-binding region in DC8-PfEMP1 variants, we expressed individual recombinant protein domains (Supplementary Table 2 ) from IT4VAR20 and two other DC8 variants (IT4VAR19 and 3D7-PFD0020c), and evaluated binding to recombinant EPCR (rEPCR) by enzyme-linked immunosorbent assay (ELISA) ( Fig. 1a ). For all three proteins, EPCR binding mapped to the CIDRa1.1 domain within DC8 and not to other extracellular domains. Using surface plasmon resonance (SPR) ( Fig. 1c and Supplementary Fig. 2 ), the binding kinetics of the IT4VAR20CIDRa1.1::EPCR interaction (dissociation constant (K d ) ,29 nM) was similar to that of the full-length protein (K d ,10 nM). This affinity is comparable to the binding of APC to EPCR, for which a K d of 32 nM has been reported 14 . These data confirmed that the DC8 CIDRa1.1 domain binds ECPR with a high and physiologically relevant affinity.
Previous work has shown that the N-terminal CIDR domain of PfEMP1 has diverged in sequence and functional properties. Whereas group B and C PfEMP1 variants bind CD36, group A and B/A PfEMP1 variants do not 15 . To investigate EPCR binding, a panel of 28 different CIDR variants representing both CD36-binding (CIDRa2-6) and non-CD36-binding subtypes (CIDRa1, d subtypes) were tested. Also included were full-length VAR2CSA and VAR3 (DC3) ( Fig. 1b ). All of the CIDRa1.1 and CIDRa1.4 proteins, representing DC8 and DC13 from different parasite genomes, bound EPCR ( Fig. 1 and Supplementary Fig. 2 ). In addition, the group A CIDRa1.5 (DC15) and CIDRa1.7 proteins also bound EPCR. By contrast, other group A CIDR domains representing DC1 (CIDRa1.2/1.3), DC4 (CIDRa1.6), and PfEMP1 variants that facilitate rosetting between infected and uninfected erythrocytes (CIDRd) 16 did not bind EPCR; neither did group B CIDRa domains, VAR2CSA or VAR3 ( Fig. 1b ). As expected, the two group B CIDRa domains bound with high affinity to CD36 (K d ,12 nM) ( Fig. 1c and Supplementary Fig. 2 ). These results show that most PfEMP1 proteins have diverged into CD36-binding (group B and C) and EPCR-binding types (group A and DC8), although the binding properties of a small subset of group A variants containing CIDRa1.2, 1.3 or 1.6, or atypical CIDR sequence types (CIDRb, c, d) remain unknown.
Next we tested whether P. falciparum-infected erythrocytes expressing native DC8 PfEMP1 bound EPCR on endothelial cells. An FCR3/ IT parasite line expressing IT4VAR20 was generated ( Supplementary  Fig. 3 ) and found to bind human brain microvascular endothelial cells (HBMECs) via the PfEMP1::EPCR interaction, as demonstrated by reversal of binding by rEPCR, anti-EPCR antibodies and antibodies against either the full-length rIT4VAR20 or the IT4VAR20-CIDRa1.1 domain ( Fig. 2 and Supplementary Figs 4 and 5 ). Recombinant intercellular adhesion molecule 1 (ICAM1), anti-ICAM1 antibodies, or antibodies against heterologous PfEMP1 domains did not inhibit binding. The binding of VAR2CSA-expressing parasites to chondroitin sulphate A (CSA), or platelet endothelial cell adhesion molecule 1 (PECAM1)-mediated binding of IT4VAR02 (DC16-DC5 PfEMP1)expressing parasites to transformed human bone marrow endothelial cells, were not inhibited by rEPCR, anti-EPCR-antibodies or the antibodies against recombinant IT4VAR20 ( Supplementary Table 3 ). To confirm these findings, a further three DC8-expressing parasite lines (FCR3 IT4VAR19, FCR3 IT4VAR06 and 3D7 PFD0020c) were generated ( Supplementary Fig. 3 ) and all were found to bind brainderived endothelial cells via EPCR ( Supplementary Table 3 ). Previous work has shown that DC8 and DC13 variants selected on brain endothelial cells also bind to non-brain microvascular endothelial cells from the heart and lung 4, 5 . Binding of the FCR3 IT4VAR19b parasite line (previously described 4 ) to brain, heart, lung and bone marrow endothelial cells was evaluated and found to be mediated by EPCR ( Supplementary Table 3 ). Altogether, these results demonstrate cytoadhesion of DC8-PfEMP1-expressing infected erythrocytes via EPCR on endothelial cells of diverse tissue origin.
Next, we explored the EPCR-binding phenotype of two parasite isolates (1983 and 1965) from African children with severe malaria. As reported previously 3 , the ex vivo var transcript profiles of these isolates were dominated by DC8-coding transcripts. The isolates cryopreserved at diagnosis were thawed, cultured and selected on rEPCR before the var transcript profile and binding phenotypes were established. The analyses showed that the cultured parasites predominantly expressed the DC8-encoding genes detected when the children were diagnosed ( Supplementary Fig. 6 ), and that the parasite lines bound to brain endothelial cells via EPCR ( Supplementary Table 3 ). This suggests that the parasites causing severe malaria in these children expressed EPCR-binding PfEMP1. To extend this observation, the binding phenotypes of 15 severe malaria, 5 uncomplicated and 10 mild malaria isolates were compared (Table 1 and Supplementary Table 4 ). Parasites were snap frozen at diagnosis, thawed and exposed to shortterm in vitro culture (2-12 parasite divisions, without rEPCR selection) APC IT4VAR20 CIDRα1.1
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to give them an opportunity to recover and expand in sufficient numbers for the binding assay. As previously reported 17 , binding to ICAM1 was higher in parasites causing severe malaria than in the control parasites (P , 0.03 and P 5 0.0016 for parasites from children with uncomplicated and mild malaria, respectively). Among parasites from patients with severe malaria, EPCR binding was significantly higher than ICAM1 binding as measured in two independent assays (P 5 0.01 and P , 0.05, respectively), and EPCR binding was significantly higher among parasites causing severe malaria than in control parasites (P 5 0.0078 and P 5 0.0009 for parasites from children with uncomplicated and mild malaria, respectively). These data show that EPCR binding is a common phenotype of parasites causing severe malaria, although studies including a larger number of children with different clinical manifestations will be needed to disentangle the role of EPCR binding in different forms of severe malaria.
The pathogenesis of complicated malaria is far from completely understood and it is likely that there are several paths leading to severe outcomes. However, most of the pathology seems to be linked to an unrestrained inflammatory reaction in response to unchecked parasite growth. EPCR has been described as the ''cell surface conductor of cytoprotective coagulation factor signaling'' 13 and, interestingly, APC-EPCR-induced PAR1 signalling downregulates 5 of the 13 previously described PfEMP1 ligands, including ICAM1 (ref. 6) . We used SPR to investigate whether PfEMP1 might interfere with EPCR-mediated activation of APC. Pre-incubation of EPCR with either DC8-CIDRa1.1 or DC13-CIDRa1.4 domains prevented binding of APC ( Fig. 1d and Supplementary Fig. 2b ). This indicated that the DC8 domain and APC competed for the same binding site. This was confirmed by showing that monoclonal antibody RCR-252 (ref. 18) , an antibody that blocks APC binding to EPCR, also prevented parasite binding to endothelial cells ( Supplementary Fig. 4 ). However, the affinity (K d 5 1 mM) of the commercial human purified APC used here was lower than that reported earlier for native APC 14 . Thus, the extent to which native soluble APC can inhibit parasite binding remains to be explored. Taken together, these findings indicate that adhesion of DC8-expressing parasites to brain endothelial cells is mediated by PfEMP1 interacting with EPCR at or close to the RCR-252 antibody-binding site. It further suggests that PfEMP1 binds EPCR near or at the same region as APC. Thus, EPCR-mediated parasite cytoadhesion could interfere with activation of cytoprotective and anti-inflammatory pathways, which in turn may contribute to severe malaria pathology ( Supplementary Fig. 1 ).
Soluble EPCR is shed from endothelial cells by the metalloproteinase tumour necrosis factor-a converting enzyme (TACE) (also known as a disintegrin and metalloproteinase-17 (ADAM17)) and circulates in plasma 19 . The levels of soluble EPCR differ between individuals, and high plasma levels of EPCR (up to 500 ng ml 21 ) are associated with specific PROCR haplotypes 20 , which in turn are associated with a higher risk of contracting venous thrombosis 21 . Of interest, with the addition of soluble rEPCR at levels between 15-300 ng ml 21 , a progressively higher inhibition of the binding between DC8expressing parasites and endothelial cells was seen (Fig. 2b) . It is a possibility worthy of further exploration that human polymorphism in EPCR is a balanced polymorphism protecting individuals against severe malaria at the expense of a higher risk of thrombotic disease.
Our findings identify EPCR binding as a property of PfEMP1. Previous studies that aimed to link parasite-binding phenotypes to disease outcome have not tested for binding to EPCR and results have . HBMECs, human brain microvascular endothelial cells. Binding was measured in medium and in the presence of rEPCR (60 mg ml 21 or as indicated), anti-EPCR IgG (aEPCR, 20 mg ml 21 ), anti-ICAM1 IgG (aICAM1, 20 mg ml 21 ), anti-rIT4VAR20 IgG (aFL IT4VAR20, 500 mg ml 21 ), anti-CIDRa1.1 IgG (aCIDRa1.1, 500 mg ml 21 ) or control IgG against a recombinant PfEMP1 containing DC5 (aDC5 IT4VAR02, 500 mg ml 21 ). P values for comparisons were evaluated using the Wilcoxon test for paired differences. RESEARCH LETTER been conflicting. Most consistently, ICAM1 binding and rosetting have been identified as virulence factors 22 . However, the fact that DC8 and other EPCR-binding variants are frequently expressed in parasites infecting young children with limited malaria immunity 23, 24 , and the ubiquity of endothelial cells expressing EPCR, suggest that CIDRa1::EPCR-mediated P. falciparum cytoadhesion is the major virulence phenotype for severe malaria. Intriguingly, in a small number of case reports a recombinant form of APC (drotrecogin alfa) [25] [26] [27] was used successfully to treat severe malaria infections with remarkable recoveries. The results presented here open new avenues for studies of malaria pathogenesis, and possibilities for the development of new adjunct therapy and vaccines to treat or protect children from death from malaria.
METHODS SUMMARY
Recombinant proteins were produced in insect 23 or Escherichia coli 4 cells (Supplementary Table 2 ), and anti-PfEMP1 antibodies were prepared as described 4, 5, 28 . Potential PfEMP1-binding partners were screened using Retrogenix methodology. PfEMP1::EPCR interactions were analysed by ELISA and SPR. Malaria parasites were cultured and PfEMP1 expression was determined using quantitative PCR, DBLa tag determination and flow cytometry 3, 28 . The history of each parasite line is given in Methods. In Copenhagen, parasite adhesion assays were performed using robotic washing and radioactively labelled parasites. HBMECs 29 were provided by M. Stins (Johns Hopkins University). In Seattle, parasite binding assays were performed using endothelial cells from different tissues on glass slides. Unbound parasites were moved by inverting slides in medium and binding quantified by microscopy. Bone marrow endothelial cells were provided by K. Kellar (Centers for Disease Control and Prevention).
